LUPIN.NS - Lupin Limited

NSE - NSE Real Time Price. Currency in INR
902.90
+3.25 (+0.36%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close899.65
Open898.00
Bid902.90 x 0
Ask0.00 x 0
Day's Range881.65 - 909.30
52 Week Range723.65 - 1,177.45
Volume3,660,767
Avg. Volume2,124,969
Market Cap406.97B
Beta-0.13
PE Ratio (TTM)162.98
EPS (TTM)5.54
Earnings DateN/A
Forward Dividend & Yield7.50 (0.82%)
Ex-Dividend Date2017-07-24
1y Target Est951.98
  • Lupin Limited (NSE:LUPIN) Investors Are Paying Above The Intrinsic Value
    Simply Wall St.8 days ago

    Lupin Limited (NSE:LUPIN) Investors Are Paying Above The Intrinsic Value

    I am going to run you through how I calculated the intrinsic value of Lupin Limited (NSEI:LUPIN) using the discounted cash flow (DCF) method. If you want to learn moreRead More...

  • Reuters11 days ago

    Sensex hits over four-month closing high

    (Reuters) - Indian shares rose on Tuesday, in line with broader Asian peers, as sentiment turned upbeat after U.S. President Donald Trump and North Korean leader Kim Jong Un pledged to work towards complete ...

  • Is Lupin Limited’s (NSE:LUPIN) PE Ratio A Signal To Sell For Investors?
    Simply Wall St.18 days ago

    Is Lupin Limited’s (NSE:LUPIN) PE Ratio A Signal To Sell For Investors?

    Lupin Limited (NSEI:LUPIN) is trading with a trailing P/E of 138.9x, which is higher than the industry average of 25.3x. While LUPIN might seem like a stock to avoid orRead More...

  • What Do Analysts Think About Lupin Limited’s (NSE:LUPIN) Earnings Trend?
    Simply Wall St.26 days ago

    What Do Analysts Think About Lupin Limited’s (NSE:LUPIN) Earnings Trend?

    In March 2018, Lupin Limited (NSEI:LUPIN) announced its most recent earnings update, which signalled that the business faced a immense headwind with earnings falling by -90.18%. Below is a briefRead More...

  • Reuterslast month

    Lupin expects U.S. drug pricing pressure to ease in 2019

    Last week, Teva Pharmaceutical, the world’s largest generic drugs maker, said it planned to cut back some of the products it sells in the U.S. market. Lupin Chief Executive Vinita Gupta said she hoped Teva’s move would create space for to rival Indian drugmakers like Lupin to grow. “We do believe the worst is over,” Gupta said on a post-earnings media call on Wednesday.

  • Reuterslast month

    India's Lupin expects U.S. drug pricing pressure to ease in 2019

    India's second-largest drugmaker Lupin Ltd said on Wednesday it expected pressure on drug prices in the United States, which has hit its profits, to ease this year as larger rivals reduce their exposure there. Last week, Teva Pharmaceutical, the world’s largest generic drugs maker, said it planned to cut back some of the products it sells in the U.S. market. Lupin Chief Executive Vinita Gupta said she hoped Teva’s move would create space for to rival Indian drugmakers like Lupin to grow.

  • Lupin Limited (NSE:LUPIN): Does The Earnings Decline Make It An Underperformer?
    Simply Wall St.2 months ago

    Lupin Limited (NSE:LUPIN): Does The Earnings Decline Make It An Underperformer?

    Analyzing Lupin Limited’s (NSEI:LUPIN) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...

  • Is Lupin Limited (NSE:LUPIN) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Lupin Limited (NSE:LUPIN) A Financially Sound Company?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Lupin Limited (NSEI:LUPIN), with a market capitalization of ₹363.61B, rarely draw their attention from the investing community.Read More...

  • February Stocks Insiders Just Bought
    Simply Wall St.4 months ago

    February Stocks Insiders Just Bought

    Insiders buying more shares in their own company indicates confidence in management’s outlook in the future. Research from MIT suggests stocks that have recently seen insider buying outperformed the marketRead More...

  • Reuters5 months ago

    Lupin third-quarter profit misses estimates on lower sales in North America, forex losses

    Indian pharmaceutical companies have struggled with weak sales in the United States on account of regulatory bans and warnings over quality control violations at production plants. Lupin said its sales in North America, which accounts for more than a third of its total sales, fell 34 percent to 14.32 billion rupees ($223.29 million). Net sales slipped 11.5 percent to 39 billion rupees.

  • Plans to Slash Medical Costs in America Run Into Generic Drug Concerns
    Bloomberg6 months ago

    Plans to Slash Medical Costs in America Run Into Generic Drug Concerns

    As U.S. regulators push hundreds of new generic drugs to market in an effort to drive down prices, the industry is facing a continuing problem in India, where many copycat medicines are manufactured.

  • Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped
    Reuters7 months ago

    Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

    (Reuters) - Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers ...

  • FDA Warns India's Lupin Over Generic Drug Quality Violations
    Bloomberg7 months ago

    FDA Warns India's Lupin Over Generic Drug Quality Violations

    Lupin Ltd., which makes generic antibiotics, antidepressants and heart medications for sale in the U.S., was warned by the Food and Drug Administration for repeatedly ignoring tests showing that pills ...

  • Reuters8 months ago

    Lupin Q2 profit falls on lower U.S. sales, but beats estimates

    REUTERS - Drugmaker Lupin Ltd (LUPN.NS) said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened ...

  • Reuters8 months ago

    India's Lupin Q2 profit falls on lower U.S. sales, but beats estimates

    Indian drugmaker Lupin Ltd said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened sales. The ...

  • Business Wire8 months ago

    Lupin Acquires Symbiomix Therapeutics LLC

    Pharma major Lupin announced that its US subsidiary, Lupin, Inc., has acquired Symbiomix Therapeutics, LLC. Lupin had entered into an option to acquire the company earlier this year.

  • Nifty, Sensex end higher; investors eye Sept-quarter results
    Reuters8 months ago

    Nifty, Sensex end higher; investors eye Sept-quarter results

    REUTERS - Indian shares rose for a third straight session on Tuesday but the gains were capped as investors hedged their bets before September-quarter corporate results kick in later this week. The benchmark ...

  • Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge
    Bloomberg9 months ago

    Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge

    While India’s largest pharmaceutical companies have seen drug approvals in the U.S. slow overall, their research and development spending has been on a run. Not so for Aurobindo Pharma Ltd.Quarter after ...

  • Reuters11 months ago

    India's Lupin Q1 profit slumps, misses estimates

    Indian drugmaker Lupin Ltd said on Wednesday first quarter profit fell 59 percent, well below analysts' estimates, as regulatory hurdles and pricing pressure in the United States, its biggest overseas market, weighed. Lupin, which specialises in oral contraceptives and drugs to treat diabetes and hypertension, said sales in the United States fell about 27 percent to 16.02 billion rupees, while domestic sales were down 1.8 percent at 9.32 billion rupees. Analysts on average expected Lupin to post a profit of 4.79 billion rupees, Thomson Reuters data showed.

  • What You Don't Know About Generic Drugs, and How It Can Hurt You
    Bloomberglast year

    What You Don't Know About Generic Drugs, and How It Can Hurt You

    To keep his anxiety under control, Peter, a 35-year-old government employee, relied for nine years on a blue-and-white pill he popped every night before bed: Cymbalta, made by Eli Lilly & Co. When a generic ...